Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oxyquinoline sulfate (commonly known as quinosol) is a small-molecule antiseptic, disinfectant, and metal chelator. It is the sulfate salt of 8-hydroxyquinoline, which exhibits broad-spectrum antibacterial, antifungal, and amebicidal activities. Quinosol functions primarily by chelating essential divalent metal ions (such as copper, zinc, iron, and manganese), thereby disrupting microbial metal homeostasis, inhibiting metalloenzymes, and generating intracellular oxidative stress. In Brazil, it is manufactured by Laboratorio Daudt Oliveira as an active ingredient in the topical oropharyngeal antiseptic product Malvatricin, which is formulated as a mouth rinse, lozenge, or spray for the treatment of sore throat (pharyngitis), mouth sores (aphthae), and other oropharyngeal infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oxyquinoline sulfate.